References
- Aggarwal BB (2003). Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol, 3, 745-56. https://doi.org/10.1038/nri1184
- Bao W, Fu HJ, Jia LT, et al (2010). HER2-mediated upregulation of MMP-1 is involved in gastric cancer cell invasion.Arch Biochem Biophys, 499, 49-55. https://doi.org/10.1016/j.abb.2010.05.009
- Castigli E, Scott S, Dedeoglu F, et al (2004). Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci, 101, 3903-8. https://doi.org/10.1073/pnas.0307348101
- Cho-Chung YS (2003). Antisense DNAs as targeted genetic medicine to treat cancer. Arch Pharm Res, 26, 183-91. https://doi.org/10.1007/BF02976827
- Cho-Chung YS, Park YG, Lee YN (1999). Oligonucleotides as transcription factor decoys. Curr Opin Mol Ther, 1, 386-92.
- Cunningham D, Allum WH, Stenning SP, et al (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New Eng J Med, 355, 11-22. https://doi.org/10.1056/NEJMoa055531
- Hahne M, Kataoka T, Schroter M, et al (1998). APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med, 188, 1185-90 https://doi.org/10.1084/jem.188.6.1185
- Hohenberger P, Gretschel S (2003). Gastric cancer. Lancet, 362, 305-15. https://doi.org/10.1016/S0140-6736(03)13975-X
- Huang WL, Zhu XF (2005). Signal Transduction [M]. Beijing: People'8 Medical Publishing House, 151-99.
- Jemal A, Siegel R, Ward E, et al (2006). Cancer statistics, 2006. CA Cancer J Clin, 56, 106-30. https://doi.org/10.3322/canjclin.56.2.106
- Konturek PC, Konturek SJ, Sulekova Z, et al (2001). Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl-2, and gastrin in human gastric cancer. Aliment Pharmacol Ther, 15, 989-99. https://doi.org/10.1046/j.1365-2036.2001.01003.x
- Kurehara H, Ishiguro H, Kimura M, et al (2007). A novel gene, RSRC2, inhibits cell proliferation and affects survival in esophageal cancer patients. Int J Oncol, 30, 421-8.
- Lei XY, Zhong M, Feng LF, et al (2005). Silencing of Bcl-XL expression in human MGC-803 gastric cancer cells by siRNA. Acta Biochim Biophys Sin, 37, 555-60. https://doi.org/10.1111/j.1745-7270.2005.00077.x
- Li Q, Zhang N, Jia Z, et al (2009). Critical role and regulation of transcription factor FoxM 1 in human gastric cancer angiogenesis and progression. Cancer Res, 69, 3501-9. https://doi.org/10.1158/0008-5472.CAN-08-3045
- Litinskiy MB, Nardelli B, Hilbert DM, et al (2002). DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol, 3, 822-9. https://doi.org/10.1038/ni829
- Lopez-Fraga M, Fernandez R, Albar JP, et al (2001). Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep, 2, 945-51. https://doi.org/10.1093/embo-reports/kve198
- Macdonald JS, Smalley SR, Benedetti J, et al (2001). Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Eng J Med, 345, 725-30. https://doi.org/10.1056/NEJMoa010187
- Mackay F, Ambrose C (2003). The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev, 14, 311-24. https://doi.org/10.1016/S1359-6101(03)00023-6
- Mackay F, Schneider P, Rennert P, et al (2003). BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol, 21, 231-64. https://doi.org/10.1146/annurev.immunol.21.120601.141152
- Medema JP, Planelles-Carazo L, Hardenberg G, et al (2003). The uncertain glory of APRIL. Cell Death Differ, 10, 1121-5. https://doi.org/10.1038/sj.cdd.4401291
- Petty RD, Samuel LM, Murray GI, et al (2009). APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. BMC Cancer, 9, 434.
- Rennert P, Schneider P, Cachero TG, et al (2000). A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med, 192, 1677-84 https://doi.org/10.1084/jem.192.11.1677
- Stadtlander CT, Waterbor JW (1999). Molecular epidemiology, pathogenesisand prevention of gastric cancer. Carcinogenesis, 20, 2195-208. https://doi.org/10.1093/carcin/20.12.2195
- Stein JV, Lopez-Fraga M, Elustondo FA, et al (2002). APRIL modulates B and T cell immunity. J Clin Invest, 109, 1587- 98. https://doi.org/10.1172/JCI0215034
- Stephens AC, Rivers RPA (2003). Antisense oligonucleotide therapy in cancer. Curr Opin Mol Ther, 5, 118-22.
- Wu CW, Chi CW, Lin WC (2002). Gastric cancer: prognostic and diagnostic advances. Expert Rev Mol Med, 4, 1-12.
- Xie Y, Yin Y, Li L, et al (2009). Short interfering RNA directed against the E2F-1 gene suppressinggastric cancer progression in vitro. Oncol Rep, 21, 1345-53.
- Xu R, Sato N, Yanai K (2009). Enhancement of paclitaxelinduced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells. Anticancer Res, 29, 261-70.
- Zhang JF, Mao ZB, Xu Z, et al (2009). Pathological significance of expression of a proliferation-inducing ligand and its receptor mRNAs in human gastric carcinoma. Acta Academiae Medicinae Nantong, 29, 98-100.
Cited by
- RNA Interference: a Promising Therapy for Gastric Cancer vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5509